Xlife Sciences AG / Key word(s): Market launch/Product Launch Xlife Sciences AG Reports Success in Liver Diagnostics – x-nuclear diagnostics GmbH Achieves Market Readiness 26.06.2024 / 07:00 CET/CEST Zurich, 26th of June 2024: Xlife Sciences AG announces significant progress in the development and application of innovat [ … ]

Xlife Sciences AG / Key word(s): Alliance/Merger Xlife Sciences AG Announces Strategic Merger Between palleos healthcare GmbH and OCT Clinical GmbH 27.05.2024 / 07:00 CET/CEST Zurich, 27th of May 2024: Xlife Sciences AG announces the merger of its portfolio company, palleos healthcare GmbH, with OCT Clinical GmbH. This  [ … ]

Zurich, 30st of April 2024: Xlife Sciences AG (SIX: XLS) released the 2023 Valuation Report today, which assesses the company's portfolio as of the end of 2023. The evaluation was conducted by the independent consulting firm CYLAD Experts and covers 18 of the total 25 project companies of Xlife Sciences1. The assessment is primarily based on the ri [ … ]

Zurich, 23rd of April 2024: Xlife Sciences AG (SIX: XLS) reports on the financial and operational results of 2023 and provides insights into plans for 2024. Despite global uncertainties, the company remains resilient thanks to innovative projects and strategic partnerships, managing to complete its first cash-effective exits. Operational Progress i [ … ]

Xlife Sciences AG / Key word(s): Alliance/Contract Xlife Sciences AG Announces Collaboration Agreement Between its Portfolio Company FUSE-AI GmbH and T-Systems Switzerland 03.04.2024 / 17:00 CET/CEST Xlife Sciences is pleased to announce a collaboration between its portfolio company, FUSE-AI, and T-Systems Switzerland.  [ … ]

Xlife Sciences AG / Key word(s): Alliance/Letter of Intent Xlife Sciences AG Expands Collaboration with Department of Health Abu Dhabi, Partners with Thermo Fisher Scientific and Masdar City 05.02.2024 / 07:00 CET/CEST Xlife Sciences AG is excited to announce the expansion of its existing collaboration with the Departme [ … ]